442 related articles for article (PubMed ID: 25553994)
81. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
[TBL] [Abstract][Full Text] [Related]
82. Extensively drug-resistant Acinetobacter baumannii bacteraemia in a multidisciplinary intensive care unit during a 6-year period: Risk factors for fulminant sepsis.
Katsiari M; Mavroidi A; Platsouka ED; Nikolaou C
J Glob Antimicrob Resist; 2018 Sep; 14():51-57. PubMed ID: 29471109
[TBL] [Abstract][Full Text] [Related]
83. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia.
Zeng J; Zhang L; Gao M; Wu J; Wu H; Chen J; Chen X; Tang W
Int J Infect Dis; 2017 Aug; 61():23-26. PubMed ID: 28572073
[TBL] [Abstract][Full Text] [Related]
84. Risk and Prognostic Factors for Multidrug-Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China.
Liu Q; Li W; Du X; Li W; Zhong T; Tang Y; Feng Y; Tao C; Xie Y
PLoS One; 2015; 10(6):e0130701. PubMed ID: 26083415
[TBL] [Abstract][Full Text] [Related]
85. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain.
Merino M; Poza M; Roca I; Barba MJ; Sousa MD; Vila J; Bou G
Microb Drug Resist; 2014 Aug; 20(4):259-63. PubMed ID: 24328852
[TBL] [Abstract][Full Text] [Related]
86. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii.
Kwon SH; Ahn HL; Han OY; La HO
Biol Pharm Bull; 2014; 37(3):340-6. PubMed ID: 24583855
[TBL] [Abstract][Full Text] [Related]
87. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
[TBL] [Abstract][Full Text] [Related]
88. Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: a retrospective study in the pediatric intensive care unit.
Shi J; Sun T; Cui Y; Wang C; Wang F; Zhou Y; Miao H; Shan Y; Zhang Y
BMC Infect Dis; 2020 Aug; 20(1):597. PubMed ID: 32787942
[TBL] [Abstract][Full Text] [Related]
89. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
90. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
[TBL] [Abstract][Full Text] [Related]
91. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.
Ye JJ; Lin HS; Kuo AJ; Leu HS; Chiang PC; Huang CT; Lee MH
J Infect; 2011 Nov; 63(5):351-61. PubMed ID: 21846481
[TBL] [Abstract][Full Text] [Related]
92. Risk factors for bacteremic pneumonia and mortality (28-day mortality) in patients with Acinetobacter baumannii bacteremia.
Lan M; Dongmei K; Guodong S; Haifeng Y; Guofeng C; Mengting C; Xiaoyun F
BMC Infect Dis; 2024 Apr; 24(1):448. PubMed ID: 38671347
[TBL] [Abstract][Full Text] [Related]
93. Evaluating the Impact of Antibiotic Exposures as Time-Dependent Variables on the Acquisition of Carbapenem-Resistant Acinetobacter baumannii.
Munoz-Price LS; Rosa R; Castro JG; Laowansiri P; Latibeaudiere R; Namias N; Tarima S
Crit Care Med; 2016 Oct; 44(10):e949-56. PubMed ID: 27167999
[TBL] [Abstract][Full Text] [Related]
94. Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia.
Kang FY; How CK; Wang YC; Cheng A; Yang YS; Kuo SC; Liu CP; Liu YM; Chen TL; Lee YT
Antimicrob Resist Infect Control; 2020 Sep; 9(1):160. PubMed ID: 32993810
[TBL] [Abstract][Full Text] [Related]
95. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy.
Choi IS; Lee YJ; Wi YM; Kwan BS; Jung KH; Hong WP; Kim JM
Int J Antimicrob Agents; 2016 Aug; 48(2):175-80. PubMed ID: 27423416
[TBL] [Abstract][Full Text] [Related]
96. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
[TBL] [Abstract][Full Text] [Related]
97. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
98. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
[TBL] [Abstract][Full Text] [Related]
99. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam.
Xia J; Zhang D; Xu Y; Gong M; Zhou Y; Fang X
Int J Infect Dis; 2014 Jun; 23():90-3. PubMed ID: 24726664
[TBL] [Abstract][Full Text] [Related]
100. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
